Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

FDA approves abuse-deterrent Hysingla ER

The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Five things for pharma marketers to know: Thursday, November 20

Five things for pharma marketers to know: Thursday, November 20

CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.

Ariz. film, entertainment agency adds depth to Fingerpaint

Ariz. film, entertainment agency adds depth to Fingerpaint

With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

Gilead buys priority voucher for $125M

The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.

Five things for pharma marketers to know: Wednesday, November 19

Five things for pharma marketers to know: Wednesday, November 19

Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

Tufts: drug dev costs have jumped 145%

Tufts: drug dev costs have jumped 145%

Researchers say the average cost of bringing a drug from concept to approval, and through post-approval assessments for reasons such as new doses or formulations, hovers at around $2.8 billion per drug in 2013 dollars.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

FDA delays rule on generic drug labeling amid controversy

As generic drug use soars, the agency intends to "create parity" in label-change rules for brands and generics.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Patients taking Vytorin experienced a 6.4% reduced relative risk for cardiovascular events, the company said.

EHRs blur line between marketing and assistance: researchers

EHRs blur line between marketing and assistance: researchers

A trio of doctors make a case for putting limits on digital promotions, including those in EHRs and through social networks.

FDA clears new tool for Ebola arsenal

A US Senate bill would also make treatments for the disease eligible for priority review vouchers.

Inovio sticks with prostate cancer drug

The Pennsylvania company says it will continue to develop its IO treatment, even without Roche's support.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

Health providers are embracing value-based care: survey

Health providers are embracing value-based care: survey

Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.

HBA launches new look and programming

HBA launches new look and programming

The Healthcare Women's Business Association's new look comes with a side of new programming in an effort to reach more women in more places.

Valeant wins over docs with trips, fees

Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.

2015 an "important year" for Pfizer's IO pipeline, analysts say

A 4-1BB agonist highlights a discussion with analysts on the drug giant's immunoncology pipeline, with a number of combination options to be tested next year.

Five things for pharma marketers to know: Thursday, November 13

Five things for pharma marketers to know: Thursday, November 13

Actavis and Allergan are close to a deal in the $60-billionish range; AstraZeneca is working on a Brilinta antidote; scientists find what amounts to a naturally occurring version of Merck's Zetia.

Researchers: Pharmacy deserts contribute to access issues

Researchers: Pharmacy deserts contribute to access issues

Researchers studying the distribution of brick-and-mortar pharmacies in Chicago link adherence issues with geographic barriers to care.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Servier bets on match-stick-sized drug pump for diabetes drug

In a $1 billion deal, Servier will develop and market Intarcia Therapeutics' implantable device in markets outside the US and Japan.

Demand for Harvoni limited by insurance reimbursement: KOLs

An arduous reimbursement process has put a damper on how quickly patients can receive the drug, say analysts, citing KOLs.

Five things for pharma marketers to know: Tuesday, November 12

Five things for pharma marketers to know: Tuesday, November 12

Life expectancy for patients cured of advanced HCV similar to healthy peers: study; Ackman takes a $2 billion stake in animal drugmaker Zoetis; Amgen and AstraZeneca report that brodalumab bested Stelara in psoriasis head-to-head.

Obesity drug war may be about more than marketing to the overweight

Obesity drug war may be about more than marketing to the overweight

Category news shows that marketing to the obese may mean marketing to related conditions.

Heart study results may be positive, but Vytorin boost unlikely

Heart study results may be positive, but Vytorin boost unlikely

An SEC filing by Merck suggests results of long awaited trial are favorable but come too late to have a commercial impact on sales of Vytorin and Zetia.

Omeros prepares US launch of Omidria

Transitional pass-through reimbursement status clears way for commercialization.

HHS dials back ACA enrollment forecast

The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.

Five things for pharma marketers to know: Tuesday, November 11

Five things for pharma marketers to know: Tuesday, November 11

FDA will evaluate effect of pharma commercial barrage; Pfizer settles Neurontin marketing lawsuit for $321 million; AbbVie and Gilead release top-line results on HCV combo therapies.

Merck HCV regimen only partially successful

Merck HCV regimen only partially successful

A Merck hep. C regimen that included two of its own agents paired with Gilead's Sovaldi faltered in four- and six-week regimens, according to analysts, leading to questions about the drugmaker's HCV prospects

Pradaxa antidote enters Phase III

Testing has already started abroad, and Boehringer says this is the first clinical trial that tests an antidote among patients taking a new oral anticoagulant.

Cigna lowers price of some HIV medications

The deal will cap the monthly price some patients may pay for medications such as Atripla.

Healthcare.gov reboot has new features

Patients will now be able to compare plans and identify ones that have disease-specific programs.

Five things for pharma marketers to know: Monday, November 10

Five things for pharma marketers to know: Monday, November 10

Dendreon goes Chapter 11; Mylan and Disney agree to EpiPen promotions; FDA pulls Ranbaxy generic claims for Nexium and Valcyte.

Five things for pharma marketers to know: Friday, November 7

Five things for pharma marketers to know: Friday, November 7

Woodcock says opioids without abuse-deterrent features are here to stay; UCB sells generic drug business to Advent and Avista; new antibiotic-free drug eradicates MRSA.

OPDP says sales aid for insomnia drug omits risk info

OPDP says sales aid for insomnia drug omits risk info

The Office of Prescription Drug Promotion took aim at a professional sales aid for Sciecure's insomnia drug Doral, saying the brochure omits risk info, material facts and makes unsubstantiated superiority claims.

AstraZeneca Q3 sales rise, expects harsh 2015

AstraZeneca Q3 sales rise, expects harsh 2015

The company raised guidance for the end of the year and said Ranbaxy's being bounced from the Nexium competition probably means it has esomeprazole market to itself through 2014.

Ebola patient who used bio-filtration device reportedly free of virus

A medical device from Aethlon, used on an Ebola patient with multiple organ failure, was associated with promising results.

Smart watch app snags top hackathon prize

An app that times chest compressions and prompts paramedics to administer medications won top prize at the Emergency Medicine Hackathon.

Five things for pharma marketers to know: Thursday, November 6

Five things for pharma marketers to know: Thursday, November 6

Eli Lilly's Cyramza approved for stomach and esophageal cancer; hedge fund may sue AbbVie for failed Shire acquisition; J&J's Olysio approved for use with Sovaldi.

Finding value in generic drugs with a twist

Finding value in generic drugs with a twist

Developing exclusive features from proven generics is a growing opportunity for patients as much as it is a ploy for life-cycle extension.

CDC says cervical screening rates set to miss target

CDC says cervical screening rates set to miss target

The Centers for Disease Control and Prevention says 11.4% of women are still not screened for cervical cancer.

TV and broadcast ad spend to decline: Forrester

Forrester Research says broadcast and TV will lose out to interactive marketing by 2019.

Microbiome linked to obesity

Researchers find that jet lag has an impact on the microscopic level.

Five things for pharma marketers to know: Wednesday, November 5

Five things for pharma marketers to know: Wednesday, November 5

The Hill outlines its healthcare expectations with a GOP Congress, Sanofi's executive shakeup may have an impact on MannKind's Afrezza launch, AstraZeneca's olaparib may have prostate cancer prospects, the FDA granted orphan status to an experimental Merrimack pancreatic cancer drug, and researchers are struggling to get Ebola virus samples.

Most CME payments can go unreported: CMS

Most CME payments can go unreported: CMS

CMS redefined the Sunshine CME exemption, still allowing most payments to go unreported.

Abbate to end tenure at Pacific Communications

Abbate to end tenure at Pacific Communications

Craig Sullivan is tapped to take over as president upon Abbate's retirement at the end of the year.

Mediation fails in Roche-Cipla patent battle

The two drugmakers have failed to reach an agreement.

HCB Health lands Alcon AOR

The Austin agency says it beat out FCB, Ogilvy CommonHealth, GSW Worldwide and H4B Chelsea for the work.

FDA adds language to GERD drugs

The new language is in response to a 2011 citizen's petition.

Study shows challenge of CNS drug approvals

For example: Tufts Center for the Study of Drug Development reseachers say it takes 18% longer to develop CNS drugs than it does non-CNS drugs.

Five things for pharma marketers to know: Tuesday, November 4

Five things for pharma marketers to know: Tuesday, November 4

AstraZeneca, Pharmacyclics and Janssen collab on Imbruvica; BMS to test HCV prices; WHO director general takes aim at pharma over lack of Ebola treatments.

Pradaxa bleeding episodes no different than warfarin: study

An FDA study of Medicare patients found that patients who took Pradaxa showed a reduced risk of stroke and brain hemorrhage.

UK docs against new statin guidelines

According to a survey, general practitioners are against new NHS guidelines on prescribing statins.

PDR Network merges with LDM Group

PDR Network merges with LDM Group

The new PDR significantly increases access to the EHR/EMR channel for reaching prescribers with the right message at right time.

Demand for obesity drugs creeps upwards

Demand for obesity drugs creeps upwards

Although sales have not skyrocketed, Arena and PBM Express Scripts have seen demand for prescription weight-loss medications rise, and researchers at The Obesity Society find the majority of weight-loss intervention candidates are eligible for prescription weight-loss medications.

Five things for pharma marketers to know: Monday, November 3

Five things for pharma marketers to know: Monday, November 3

Bayer Consumer consolidates agency business; Publicis offers $3.7 billion for Sapient; Boehringer Ingelheim signs option deal for fatal lung disease drug.

Five things for pharma marketers to know: Friday, October 31

Five things for pharma marketers to know: Friday, October 31

Bristol-Myers Squibb's Opdivo improves survival rate in lung cancer patients; Businessweek says new Viagra spot targets a younger audience; NIH launches database to keep track of different countries' clinical trial regulations

Medical innovations with big promise for 2015

Cleveland Clinic releases their annual list of highly promising innovations.

Withdraw FDA scientific pubs distribution guide: Public Citizen

Withdraw FDA scientific pubs distribution guide: Public Citizen

Public Citizen tells FDA it should withdraw draft guidance that it believes will allow drugmakers to tell physicians marketed drugs are less risky than their labels indicate.

Orphan drugs a niche no longer

Orphan drugs a niche no longer

Orphan drug growth will easily outpace non-orphans through 2020.

Programmatic buying stands to disrupt healthcare marketing

Programmatic buying stands to disrupt healthcare marketing

Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.

Five things for pharma marketers to know: Thursday, October 30

Five things for pharma marketers to know: Thursday, October 30

Sanofi courts AstraZeneca CEO Soriot; Teva CEO optimistic on Copaxone patent ruling; AstraZeneca scores approval of diabetes combo drug.

Ireland's drugmakers resist price cuts

The country's drug ministry has identified drugs as an area for savings.

Google foresees a disease early warning system fostered by tiny particles

Google foresees a disease early warning system fostered by tiny particles

The company unveils a plan for deploying controllable nanoparticles into peoples' bodies for monitoring health conditions.

Forbes's Matthew Herper sounds off on Viehbacher firing

Herper writes that Sanofi—without Viehbacher—is at risk of moving too slowly in an increasingly competitive industry.

India bans plastic packaging for drug liquids

Widely used plastics such as PET will have to be replaced with more costly glass containers.

Make all Rx contraceptives OTC, lawyer urges FDA

Make all Rx contraceptives OTC, lawyer urges FDA

The former FDA director of medical device compliance has petitioned the agency to make oral contraceptives over-the-counter.

Five things for pharma marketers to know: Wednesday, October 29

Five things for pharma marketers to know: Wednesday, October 29

Sanofi CEO fired; Sovaldi sales slow; Ranbaxy CEO affirms generic Nexium rights.

Pfizer undeterred from tax inversion deals

Despite the Treasury's crackdown on inversions, CEO Ian Read says they would still invert for the right deal.

Amgen has no plans to split up, layoffs continue

The drugmaker plans to cut 600-1,100 jobs next year.

Diabetes competition muddles Sanofi's future, despite strong sales

Diabetes competition muddles Sanofi's future, despite strong sales

Sanofi is expected to slash prices of its diabetes products to retain US market access.

A generic Nexium, at long last?

A generic Nexium, at long last?

With Ranbaxy's failure to launch a low-cost version of the acid reflux drug, pressure is mounting on FDA to speed a generic to market.

Five things for pharma marketers to know: Tuesday, October 28

Five things for pharma marketers to know: Tuesday, October 28

Sanofi CEO says diabetes sales will slow in 2015; Takeda/Lilly Actos settlement slashed by 99%; study says Sovaldi is cost-effective for prisoners.

Search under way to identify MM&M Healthcare Transformers

Search under way to identify MM&M Healthcare Transformers

The editorial team of MM&M announces a call for nominations for its first-ever compilation of the Top 40 Healthcare Transformers.

FDA request delays Sarepta's Duchenne drug

The drug is now expected to be filed by mid-2015, rather than by year's end.

Eisai creates contest to educate kids about epilepsy

The new initiative will look to recruit a teenager with epilepsy to appear in the next iteration of its educational comic book series.

Cancer darling can't save Merck, as sales slip for quarter

Cancer darling can't save Merck, as sales slip for quarter

The drugmaker's pharma sales fell by 4%, even as Merck's Keytruda cancer darling received another Breakthrough Therapy designation.

Five things for pharma marketers to know: Monday, October 27

Five things for pharma marketers to know: Monday, October 27

Study shows Xarelto.com is top branded website among PCPs; Janssen launches IBD educational campaign; Merck's Keytruda scores Breakthrough Therapy designation in lung cancer.

Five things for pharma marketers to know: Friday, October 24

Five things for pharma marketers to know: Friday, October 24

Ebola comes to NY; AstraZeneca drops antibiotics; FDA approves hemophilia A drug.

Video recap of the 2014 MM&M Awards

Video recap of the 2014 MM&M Awards

A highlight reel includes key moments from the Awards ceremony.

Consumers swayed by comparative drug claims: study

Consumers swayed by comparative drug claims: study

In a study to observe their effect in DTC ads, comparison claims in both print and video ads led consumers to trust those drugs over rival medications, researchers found.

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

Claims show BMS's Abilify remains strong

The antipsychotic's hold on the market has been steady, despite generics of drugs such as AstraZeneca's Seroquel.

App may diagnose glaucoma

Researchers say the iPad app could help assess vision loss.

Five things for pharma marketers to know: Thursday, October 23

Five things for pharma marketers to know: Thursday, October 23

FDA panel endorses Novartis psoriasis drug; court rules with Pfizer on cancer drug patent; drugmakers may look for indemnity against losses from Ebola vaccines.

Biogen's strong quarter eclipsed by patient death

Biogen's strong quarter eclipsed by patient death

Despite strong performance by its MS therapies, the drugmaker's robust third-quarter sales were overshadowed by the death of a patient taking Tecfidera.The patient had a rare brain infection.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Five things for pharma marketers to know: Wednesday, October 22

Five things for pharma marketers to know: Wednesday, October 22

Novo partners with YouTube star for diabetes vids; hedge fund wants Amgen to split up; J&J ramps up Ebola vaccine production.

Senate hearing may be on horizon for HCV drug prices

Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.

JAMA study links Parkinson's drugs and compulsive behavior

Researchers conclude that "more prominent warnings" are warranted for the class known as dopamine receptor agonists.

Email Newsletters

MM&M inVISION